Blue­bird hopes for 3 drug ap­provals by 2019, in­clud­ing CAR-T and gene ther­a­pies

Blue­bird bio is hop­ing for an FDA OK for three of its ex­per­i­men­tal drugs by 2019, in­clud­ing the CAR-T bb2121 part­nered with Cel­gene hat caused a buzz at ASH.

That’s ac­cord­ing to the com­pa­ny’s CEO Nick Leschly, who an­nounced blue­bird’s am­bi­tious plans dur­ing his pre­sen­ta­tion at JPM.

The CAR-T, meant to treat mul­ti­ple myelo­ma, is a new BC­MA-tar­get­ing ther­a­py that has post­ed some stel­lar clin­i­cal re­sults in an ear­ly-stage study. The FDA al­ready gave the pro­gram break­through ther­a­py des­ig­na­tion. The CAR-T was the star of ASH when blur­bird re­port­ed ex­treme­ly high re­sponse and re­mis­sion rates with good safe­ty in a small study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER